Takeda

The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths - 10 mg and 20 mg

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

Vonoprazan is a novel gastrointestinal drug and is a next generation treatment for gastro duodenal ulcer and GERD

This deal is meant to commercialise the drug in India under Cipla’s own trademark brands

Takeda Plans to Initiate Global Phase 3 Trial of Mezagitamab in ITP in the Second Half of FY2024

The new partnership aims to address widespread gastroesophageal reflux disease in India

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few…

The company aims to commercialise its gastrointestinal drug in India  Torrent Pharmaceuticals recently announced that it has…

Gary Dubin, President, Global Vaccine Business Unit, Takeda, and Dion Warren, Head of Multi-Country Organization, India &…

Takeda entered into multiple cell therapy collaborations for the development of CAR-T therapies with organizations like Memorial…